Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2

Publication

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2

Journal Paper/Review - Nov 15, 2005

Kralovics Robert, Cazzola Mario, Pietra Daniela, Passamonti Francesco, Tichelli André, Tiedt Ralph, Brutsche Martin, Buser Andreas S, Teo Soon-Siong, Skoda Radek C

Citation

Kralovics R, Cazzola M, Pietra D, Passamonti F, Tichelli A, Tiedt R, Brutsche M, Buser A, Teo S, Skoda R. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106:3374-6.

Type

Journal Paper/Review (English)

Journal

Blood 2005; 106

Publication Date

Nov 15, 2005

Issn Print

0006-4971

Pages

3374-6

Brief description/objective

We identified 13 new gene expression markers that were elevated and one marker, ANKRD15, that was down-regulated in patients with polycythemia vera (PV). These 14 markers, as well as the previously described PRV1 and NF-E2, exhibited the same gene expression alterations also in patients with exogenously activated granulocytes due to sepsis or granulocyte colony-stimulating factor (G-CSF) treatment. The recently described V617F mutation in the Janus kinase 2 (JAK2) gene allows defining subclasses of patients with myeloproliferative disorders based on the JAK2 genotype. Patients with PV who were homozygous or heterozygous for JAK2-V617F exhibited higher levels of expression of the 13 new markers, PRV1, and NF-E2 than patients without JAK2-V617F, whereas ANKRD15 was down-regulated in these patients. Our results suggest that the alterations in expression of the markers studied are due to the activation of the Jak/signal transducer and activator of transcription (STAT) pathway through exogenous stimuli (sepsis or G-CSF treatment), or endogenously through the JAK2-V617F mutation.